Urologists & Medical Oncologists (Prostate Cancer) – Paid Research Study

$175/hrRemote (United States)Contract

Apply now →

You'll finish your application on Mercor, our hiring partner: sign up and take their short AI interview.

Mercor is conducting a paid research study in collaboration with a leading AI research lab focused on improving healthcare. We are seeking board-certified urologists and medical oncologists in the United States who manage patients with metastatic prostate cancer to take part in a short online survey about treatment decision-making.

Responsibilities

Participants will be asked to:

Complete a structured ~30-minute online survey

Share perspectives on how you evaluate and select systemic treatments for patients with prostate cancer

Submit all responses within the given timeline

Requirements

Urologist or medical oncologist with an MD or DO

Board certified in your specialty

Hold an active, unrestricted US medical license and practice primarily in the United States

Spend at least 25% of your professional time in direct patient care

Have cared for prostate-cancer patients in the past 12 months , including at least one patient with metastatic hormone-sensitive (mHSPC) or castration-resistant (mCRPC) prostate cancer

Regularly manage metastatic prostate cancer , with primary or shared responsibility for selecting systemic treatment

Able to independently complete a ~30-minute online survey

Please note: this study is not open to anyone who has taken part in prostate-cancer market research in the past 3 months, or who (or whose immediate family) works for a pharmaceutical, diagnostics, market research, or advertising company, a wholesaler, or a specialty pharmacy.

Engagement Details

Format: Online survey

Duration: Approximately 30 minutes

Compensation: One-time payment upon successful verification of the submission

Location: Remote (United States)

Why Participate

Contribute to research shaping the next generation of healthcare AI tools

Share your real-world clinical expertise in managing advanced prostate cancer